These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 25351246)

  • 21. Targeted expression of mutated ALK induces neuroblastoma in transgenic mice.
    Heukamp LC; Thor T; Schramm A; De Preter K; Kumps C; De Wilde B; Odersky A; Peifer M; Lindner S; Spruessel A; Pattyn F; Mestdagh P; Menten B; Kuhfittig-Kulle S; Künkele A; König K; Meder L; Chatterjee S; Ullrich RT; Schulte S; Vandesompele J; Speleman F; Büttner R; Eggert A; Schulte JH
    Sci Transl Med; 2012 Jul; 4(141):141ra91. PubMed ID: 22764207
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ALK upregulates POSTN and WNT signaling to drive neuroblastoma.
    Huang M; Fang W; Farrel A; Li L; Chronopoulos A; Nasholm N; Cheng B; Zheng T; Yoda H; Barata MJ; Porras T; Miller ML; Zhen Q; Ghiglieri L; McHenry L; Wang L; Asgharzadeh S; Park J; Gustafson WC; Matthay KK; Maris JM; Weiss WA
    Cell Rep; 2024 Mar; 43(3):113927. PubMed ID: 38451815
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Focal DNA copy number changes in neuroblastoma target MYCN regulated genes.
    Kumps C; Fieuw A; Mestdagh P; Menten B; Lefever S; Pattyn F; De Brouwer S; Sante T; Schulte JH; Schramm A; Van Roy N; Van Maerken T; Noguera R; Combaret V; Devalck C; Westermann F; Laureys G; Eggert A; Vandesompele J; De Preter K; Speleman F
    PLoS One; 2013; 8(1):e52321. PubMed ID: 23308108
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Next-generation RNA sequencing reveals differential expression of MYCN target genes and suggests the mTOR pathway as a promising therapy target in MYCN-amplified neuroblastoma.
    Schramm A; Köster J; Marschall T; Martin M; Schwermer M; Fielitz K; Büchel G; Barann M; Esser D; Rosenstiel P; Rahmann S; Eggert A; Schulte JH
    Int J Cancer; 2013 Feb; 132(3):E106-15. PubMed ID: 22907398
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas.
    Westermann F; Muth D; Benner A; Bauer T; Henrich KO; Oberthuer A; Brors B; Beissbarth T; Vandesompele J; Pattyn F; Hero B; König R; Fischer M; Schwab M
    Genome Biol; 2008 Oct; 9(10):R150. PubMed ID: 18851746
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rapamycin inhibits proliferation of human neuroblastoma cells without suppression of MycN.
    Misawa A; Hosoi H; Tsuchiya K; Sugimoto T
    Int J Cancer; 2003 Mar; 104(2):233-7. PubMed ID: 12569580
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cell culture and Drosophila model systems define three classes of anaplastic lymphoma kinase mutations in neuroblastoma.
    Chand D; Yamazaki Y; Ruuth K; Schönherr C; Martinsson T; Kogner P; Attiyeh EF; Maris J; Morozova O; Marra MA; Ohira M; Nakagawara A; Sandström PE; Palmer RH; Hallberg B
    Dis Model Mech; 2013 Mar; 6(2):373-82. PubMed ID: 23104988
    [TBL] [Abstract][Full Text] [Related]  

  • 28. ID2 expression in neuroblastoma does not correlate to MYCN levels and lacks prognostic value.
    Vandesompele J; Edsjö A; De Preter K; Axelson H; Speleman F; Påhlman S
    Oncogene; 2003 Jan; 22(3):456-60. PubMed ID: 12545167
    [TBL] [Abstract][Full Text] [Related]  

  • 29. p19-INK4d inhibits neuroblastoma cell growth, induces differentiation and is hypermethylated and downregulated in MYCN-amplified neuroblastomas.
    Dreidax D; Bannert S; Henrich KO; Schröder C; Bender S; Oakes CC; Lindner S; Schulte JH; Duffy D; Schwarzl T; Saadati M; Ehemann V; Benner A; Pfister S; Fischer M; Westermann F
    Hum Mol Genet; 2014 Dec; 23(25):6826-37. PubMed ID: 25104850
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Activation of anaplastic lymphoma kinase is responsible for hyperphosphorylation of ShcC in neuroblastoma cell lines.
    Miyake I; Hakomori Y; Shinohara A; Gamou T; Saito M; Iwamatsu A; Sakai R
    Oncogene; 2002 Aug; 21(38):5823-34. PubMed ID: 12185581
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MYCN, neuroblastoma and focal adhesion kinase (FAK).
    Beierle EA
    Front Biosci (Elite Ed); 2011 Jan; 3(2):421-33. PubMed ID: 21196322
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anaplastic lymphoma kinase (ALK) inhibitor response in neuroblastoma is highly correlated with ALK mutation status, ALK mRNA and protein levels.
    Duijkers FA; Gaal J; Meijerink JP; Admiraal P; Pieters R; de Krijger RR; van Noesel MM
    Cell Oncol (Dordr); 2011 Oct; 34(5):409-17. PubMed ID: 21625996
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phosphoproteomic analysis of anaplastic lymphoma kinase (ALK) downstream signaling pathways identifies signal transducer and activator of transcription 3 as a functional target of activated ALK in neuroblastoma cells.
    Sattu K; Hochgräfe F; Wu J; Umapathy G; Schönherr C; Ruuth K; Chand D; Witek B; Fuchs J; Li PK; Hugosson F; Daly RJ; Palmer RH; Hallberg B
    FEBS J; 2013 Nov; 280(21):5269-82. PubMed ID: 23889739
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ALK positively regulates MYCN activity through repression of HBP1 expression.
    Claeys S; Denecker G; Durinck K; Decaesteker B; Mus LM; Loontiens S; Vanhauwaert S; Althoff K; Wigerup C; Bexell D; Dolman E; Henrich KO; Wehrmann L; Westerhout EM; Demoulin JB; Kumps C; Van Maerken T; Laureys G; Van Neste C; De Wilde B; De Wever O; Westermann F; Versteeg R; Molenaar JJ; Påhlman S; Schulte JH; De Preter K; Speleman F
    Oncogene; 2019 Apr; 38(15):2690-2705. PubMed ID: 30538293
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mutation-Independent Activation of the Anaplastic Lymphoma Kinase in Neuroblastoma.
    Regairaz M; Munier F; Sartelet H; Castaing M; Marty V; Renauleaud C; Doux C; Delbé J; Courty J; Fabre M; Ohta S; Vielh P; Michiels S; Valteau-Couanet D; Vassal G
    Am J Pathol; 2016 Feb; 186(2):435-45. PubMed ID: 26687816
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High anaplastic lymphoma kinase immunohistochemical staining in neuroblastoma and ganglioneuroblastoma is an independent predictor of poor outcome.
    Duijkers FAM; Gaal J; Meijerink JPP; Admiraal P; Pieters R; de Krijger RR; van Noesel MM
    Am J Pathol; 2012 Mar; 180(3):1223-1231. PubMed ID: 22203052
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dickkopf-1 is down-regulated by MYCN and inhibits neuroblastoma cell proliferation.
    Koppen A; Ait-Aissa R; Hopman S; Koster J; Haneveld F; Versteeg R; Valentijn LJ
    Cancer Lett; 2007 Oct; 256(2):218-28. PubMed ID: 17643814
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Emerging importance of ALK in neuroblastoma.
    Azarova AM; Gautam G; George RE
    Semin Cancer Biol; 2011 Oct; 21(4):267-75. PubMed ID: 21945349
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vasoactive intestinal peptide decreases MYCN expression and synergizes with retinoic acid in a human MYCN-amplified neuroblastoma cell line.
    Chevrier L; Meunier AC; Cochaud S; Muller JM; Chadéneau C
    Int J Oncol; 2008 Nov; 33(5):1081-9. PubMed ID: 18949372
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neuroblastoma models for insights into tumorigenesis and new therapies.
    Kiyonari S; Kadomatsu K
    Expert Opin Drug Discov; 2015 Jan; 10(1):53-62. PubMed ID: 25345447
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.